安杰思 (688581)

Hangzhou AGS MedTech Co., Ltd.

KSH

Tags

SSE 580 IndexSpecial Purpose Equipment ManufacturingMedical DevicesPharmaceuticals and HealthcareIntensive Research CoverageBelow IPO PriceSTAR Market 200 IndexHigh-Performing StocksMargin Trading and Securities Lending医药生物

K-Line Chart

No K-line data available

Company NameHangzhou Anjie Medical Technology Co., Ltd.
Listing Date2023-05-19
Issue Price125.8RMB
Registered Capital8112.207910k RMB
Legal RepresentativeZhang Cheng
Registered AddressNo. 389 Xingzhong Road, Linping District, Hangzhou City, Zhejiang Province, China
IndustryMedical Devices
Main BusinessResearch, development, production, and sales of endoscopic minimally invasive diagnostic and therapeutic devices.
Company ProfileHangzhou Anjie Medical Technology Co., Ltd. is engaged in the research, development, production, and sales of endoscopic minimally invasive diagnostic and therapeutic devices. Its main products are used in the field of digestive endoscopy diagnosis and treatment, categorized by therapeutic purpose into hemostasis and closure devices, EMR/ESD devices, biopsy devices, ERCP devices, and diagnostic and therapeutic instruments. The company's various minimally invasive diagnostic and therapeutic devices are used in conjunction with digestive endoscopes, complementing each other and jointly applied in the clinical diagnosis and treatment of digestive tract diseases. Upholding the core values of 'Innovation, Persistence, and Sharing,' the company provides safer and more efficient endoscopic minimally invasive diagnostic and therapeutic devices for patients and clinicians. Thanks to its high product quality and excellent clinical performance, the company has established a high market reputation in the endoscopic minimally invasive diagnostic and therapeutic device industry. In the domestic market, its marketing network has basically covered major cities nationwide, with leading products used in over a thousand hospitals across the country. In the international market, the company's related products have obtained certifications such as U.S. FDA registration and EU CE marking, and are sold to more than forty countries and regions including the United States, Germany, Italy, the United Kingdom, South Korea, Australia, and Japan.

Stock Details

1. Key Indicators

  • Total Shares(W): 8097.88
  • Circulating A-Shares(W): 4141.64
  • Earnings Per Share(RMB): 2.1800
  • Net Assets Per Share(RMB): 30.7254
  • Operating Revenue(W RMB): 45932.40
  • Total Profit(W RMB): 20899.08
  • **Net Profit Attributable to Parent(W RMB) **: 17700.82
  • Net Profit Growth Rate(%): -10.35
  • Weighted Return on Equity(%): 6.9500
  • Operating Cash Flow Per Share(RMB): 1.4770
  • Undistributed Profit Per Share(RMB): 7.9921
  • Capital Reserve Per Share(RMB): 21.2463

2. Main Business

The main business covers:

  • Research, development, production, and sales of endoscopic minimally invasive diagnostic and therapeutic devices

3. Company Basic Information

  • Company Name: Hangzhou AnjieSi Medical Technology Co., Ltd.
  • Listing Date: 2023-05-19
  • Industry: Special Purpose Equipment Manufacturing
  • Address: Building 5 and 6 (excluding Room 103 and Room 202), No. 597 Kangxin Road, Yuhang District, Hangzhou City, Zhejiang Province
  • Website: https://www.bioags.com
  • Company Profile: On March 11, 2019, AnjieSi Limited held a shareholders' meeting and agreed to convert AnjieSi Limited into a joint stock company. On May 29, 2019, eight institutional shareholders including Hangzhou Yijia, Da'an Gene, Ningbo Dingjie, Suzhou New Century, Paradise Silicon Valley Zhenghui, Guangzhou Da'an, Ningbo Jiayi, Ningbo Daohe, and one natural person shareholder Zhang Cheng jointly acted as promoters to convert AnjieSi Limited into a joint stock company. The conversion was based on the audited net assets of RMB 119,926,992.95 as of March 31, 2019, of which the total share capital was RMB 43,400,971. On June 20, 2019, the company completed the change registration with the Hangzhou Market Supervision Administration, with a registered capital of RMB 43.400971 million.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Guangzhou Da'an Gene Co., Ltd. Corporate Legal Person 840.00 20.28
2 Guangzhou Da'an Gene Technology Co., Ltd. Corporate Legal Person 362.55 8.75
3 Suzhou Yuansheng Private Equity Management Partnership (Limited Partnership) - Suzhou Industrial Park New Century Phase II Venture Capital Enterprise (Limited Partnership) Corporate Legal Person 288.80 6.97
4 Ping An Low-Carbon Economy Mixed Securities Investment Fund Class A Fund 85.00 2.05
5 CITIC Securities Investment Co., Ltd. Corporate Legal Person 66.74 1.61
6 Hong Kong Securities Clearing Company Ltd. Northbound Capital 42.09 1.02
7 Ping An Value Premium Mixed Securities Investment Fund Class A Fund 40.00 0.97
8 Ping An Value Select Mixed Securities Investment Fund Class A Fund 24.00 0.58
9 Xingyin Juyou Zhixuan Mixed Initiation Securities Investment Fund Class A Fund 5.37 0.13
10 Xingyin Research Select Stock Securities Investment Fund Class A Fund 3.11 0.07

5. Concept Sectors

  • Margin Trading & Securities Lending
  • Blue-Chip Stock
  • Below IPO Price
  • Intensive Research
  • STAR 200
  • SSE 580

Remarks

  • Data update date: 2025-09-30
  • Data source: Public Market Information